Molecular dynamics simulations for the structure-based drug design: targeting small-GTPases proteins

Area of Science:

• Computational chemistry and structural biology.
• Pharmacology and drug discovery.
• Molecular modeling and simulation.

Background:

• Small-Guanosine Triphosphate Phosphohydrolases (GTPases) are crucial signaling proteins implicated in numerous cellular processes and diseases.
• Deregulation of small-GTPases makes them attractive targets for therapeutic intervention.
• Recent successes in targeting KRas highlight the potential of small-molecule inhibitors for GTPase-related conditions.

Purpose of the Study:

• To review the application of Molecular Dynamics (MD) simulations in understanding small-GTPase mechanisms.
• To highlight the role of MD in assessing cancer-related variants of small-GTPases.
• To explore the potential of MD simulations in the discovery of novel small-GTPase inhibitors.

Main Methods:

• Utilizing MD simulations to capture biomolecular motions at physiological temperatures.
• Analyzing simulation data to identify allosteric binding sites and predict drug-binding poses.
• Estimating thermodynamic and kinetic properties of drug-GTPase interactions.

Main Results:

• MD simulations provide crucial insights into the dynamic behavior of small-GTPases.
• These simulations can reveal previously unknown binding pockets and guide structure-based drug design.
• MD accurately predicts drug-binding poses and estimates binding affinities.

Conclusions:

• MD simulations are invaluable tools for mechanism-based drug design targeting small-GTPases.
• Integrating AI, machine learning, and quantum computing with MD will enhance the targeting of challenging small-GTPase mutations and variants.
• This synergistic approach holds promise for developing personalized and tissue-agnostic therapies for GTPase-driven diseases.